Skip to main content

Advertisement

SpringerLink
Log in

Current Advances and Changes in Treatment Strategy May Improve Survival and Quality of Life in Patients With Potentially Curable Gastric Cancer

  • Original Article
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: The treatment strategy for gastric cancer is determined by the stage of disease. Advances in diagnostic techniques such as endoscopic ultrasound (EUS) and in staging have increased the accuracy of pretreatment staging. Correct staging is a prerequisite for the optimal treatment of gastric cancer patients. Long-term expected survival and quality of life (QOL) are the major criteria determining the therapeutic strategy.

Results: Surgical resection offers excellent survival rates for early gastric cancer (EGC) patients. D1 resection is sufficient for mucosal cancers (T1m) and for most submucosal cancers (T1sm); however, for the rest (about 5%) of these patients with N2 disease a D2 resection is required for complete tumor resection (R0). Considering QOL, endoscopic mucosal resection (EMR) or laparoscopic wedge resection is the best frontline therapy for several mucosal cancers. Prediction and selection of node-negative patients with the help of certain macroscopic and histologic criteria can eliminate the possibility for residual disease in perigastric lymph nodes. However, long-term survival data are needed before these new techniques become more generally accepted. In contrast, an aggressive approach is necessary for the treatment of advanced gastric cancer. Total gastrectomy, with the exception of distal tumors that can be treated by subtotal gastrectomy, is the procedure of choice. Splenectomy is indicated for proximal advanced tumors. Distal pancreatectomy should be avoided, however, because its adverse effect has been documented in all randomized trials. Although the survival benefit of extended (D2) lymphadenectomy is unproven in randomized trials, D2 resection increases the R0 resection rate and may improve survival in some selected nodepositive patients. D2 resection has little effect on preventing peritoneal tumor spread and liver metastasis, and the traditional late administration of chemotherapeutic drugs has been proven ineffective. Current data suggest a possible beneficial effect of combined treatment for patients with local advanced gastric cancer (LAGC). Ongoing phase III randomized trials will prove whether patients with LAGC treated by neoadjuvant chemotherapy plus D2 resection versus surgery alone or surgery plus intraoperative intraperitoneal chemotherapy derive any benefit from these combined treatment modalities.

Conclusion: Evaluation of all information concerning tumor stage, location, histologic type, expected survival, and QOL after resection is of paramount importance for the surgeon planning the extent of surgery. The therapeutic approach should be stratified according to the stage of disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Whelan SL, Parkin DM, Masuyer E, eds. Trends in cancer incidence and mortality. IARC Scientific Publication No. 102. Lyon, France: IARC Scientific Publications, 1993.

    Google Scholar 

  2. Cancer Statistics. Registrations: England and Wales. London: HM Stationery Office, 1989.

    Google Scholar 

  3. Allum WH, Powell DJ, McConkey CC, Fielding JWL. Gastric cancer: a 25-year review. Br J Surg 1989;76:535–40.

    PubMed  CAS  Google Scholar 

  4. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G, Winchester D, Osteen R. Cancer of the stomach: a patient care study by the American College of Surgeons. Ann Surg 1993;218:583–7.

    PubMed  CAS  Google Scholar 

  5. Akoh JA, MacIntyre IMC. Improving survival in gastric cancer: review of 5- year survival rates in English language publications from 1970. Br J Surg 1992;79:293–9.

    PubMed  CAS  Google Scholar 

  6. Jentschura D, Heubner C, Manegold BC, Rumstadt B, Winkler M, Trede M. Surgery for early gastric cancer: a European one-center experience. World J Surg 1997;21:845–9.

    PubMed  CAS  Google Scholar 

  7. Nakajima T, Nishi M. Surgery and adjuvant chemotherapy for gastric cancer. Hepatogastroenterology 1989;36:79–85.

    PubMed  CAS  Google Scholar 

  8. Iriyama K, Asakawa T, Koike H, Nishiwaki H, Suzuki H. Extensive lymphadenectomy necessary for surgical treatment of intramucosal carcinoma of the stomach? Arch Surg 1989;124:309–11.

    PubMed  CAS  Google Scholar 

  9. Folli S, Dente M, Dell’amore D, Nanni O, Saragoni L, Vio A. Early gastric cancer: prognostic factors in 223 patients. Br J Surg 1995;62:952–6.

    Google Scholar 

  10. Sasako M, McCulloch P, Kinoshita T, Marujama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 1995;82:346–51.

    PubMed  CAS  Google Scholar 

  11. Park CH, ParkSM, Kim IC. Treatment strategies for early gastric cancer. In: Siewert JR, Roder JD, eds. Proceedings of the 2nd International Gastric Cancer Congress, Munich, 1997:1, 841–4.

  12. Nagashima T, Ueno I, Kobayashi N, et al. Endoscopic mucosal resection for early gastric cancer. In: Siewert JR, Roder JD, eds. Proceedings of the 2nd International Gastric Cancer Congress Munich, 1997:1, 845–8.

  13. Kitamura K, Yamaguchi T, Taniguchi H, Hagiwara A, Sawai K, Takahashi T. Analysis of lymph node metastasis in early gastric cancer: rationale of limited surgery. J Surg Oncol 1997;64:42–7.

    CAS  PubMed  Google Scholar 

  14. Hanazaki K, Wakabayashi M, Sodeyama W, et al. Surgical outcome in early gastric cancer with lymph node metastasis. Hepatogastroenterology 1997;44:907–11.

    PubMed  CAS  Google Scholar 

  15. Seto Y, Nagawa H, Muto Y. Impact of lymph node metastasis on survival with early gastric cancer. World J Surg 1997;21:186–9.

    PubMed  CAS  Google Scholar 

  16. Sano T, Sasako M, Kinoshita T, Marujama K. Recurrence of early gastric cancer: follow-up of 1475 patients and review of the Japanese literature. Cancer 1993;72:3174–8.

    PubMed  CAS  Google Scholar 

  17. Sano T, Kibori O, Muto T. Lymph node metastasis from early gastric cancer: endoscopic resection of tumour. Br J Surg 1992;79:241–4.

    PubMed  CAS  Google Scholar 

  18. Hiki Y, Shimao H, Mieno H, Sakakibara Y, Kobayashi N, Saigenji K. Modified treatment of early gastric cancer: evaluation of endoscopic treatment of early gastric cancers with respect to treatment indications groups. World J Surg 1995;19:517–22.

    PubMed  CAS  Google Scholar 

  19. Ohgami M, Otani Y, Kitajima M. Laparoscopic surgery for early gastric cancer—its advantage and pitfall. Gan To Kagaku Ryoho 1997;24:532–7.

    PubMed  CAS  Google Scholar 

  20. Yanai H, Tada M, Karita M, Okita K. Diagnostic utility of 20-megahertz linear endoscopic ultrasonography in early gastric cancer. Gastrointest Endosc 1996;44:29–33.

    PubMed  CAS  Google Scholar 

  21. Akahoshi K, Chijiwa Y, Sasaki I, et al. Pre-operative TN staging of gastric cancer using a 15 MHZ ultrasound miniprobe. Br J Radiol 1997;70:703–7.

    PubMed  CAS  Google Scholar 

  22. Siewert JR, Kestlmeier R, Busch R, et al. Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases. Br J Surg 1996;83:1144 –7.

    CAS  PubMed  Google Scholar 

  23. Roukos DH. Extended lymphadenectomy in gastric cancer: When, for whom and why. Ann Roy Coll Surg Engl 1998;80:16–24.

    CAS  Google Scholar 

  24. Japanese Research Society for Gastric Cancer. The general rules for the gastric cancer study in surgery and pathology. Jpn J Surg 1981;11:127–39.

    Google Scholar 

  25. Gouzi JL, Huguier M, Fagniez PL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 1989;209:162–6.

    PubMed  CAS  Google Scholar 

  26. Marujama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987;11:418–25.

    Google Scholar 

  27. Siewert JR, Boettcher K, Roder JD, Busch R, Hermanek P, Meyer HJ, and the German Gastric Carcinoma Study Group. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. Br J Surg 1993;80:1015–8.

    PubMed  CAS  Google Scholar 

  28. Okajima K, Isozaki H. Splenectomy for treatment of gastric cancer: Japanese experience. World J Surg 1995;19:537–40.

    PubMed  CAS  Google Scholar 

  29. Roukos D, Hottenrott C, Lorenz M, Encke A. Stadien-und Lokalisationsgerechte Chirurgie zur Milzerhaltung beim Magenkarzinom. Akt Chir 1989; 24:96–101.

    Google Scholar 

  30. Robertson CS, Chung SCS, Woods SDS, et al. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994;220:176–82.

    CAS  PubMed  Google Scholar 

  31. Roukos D, Schmidt-Mathiesen A, Encke A. Adenocarcinoma of the gastric antrum: does D2 total gastrectomy with splenectomy improve prognosis compared to D1 subtotal gastrectomy? A longterm survival analysis with emphasis on Lauren classification. Surg Oncol 1995;4:323–32.

    Article  PubMed  CAS  Google Scholar 

  32. Brady MS, Rogatho A, Dent LL, Shiou MH. Effect of splenectomy on morbidity and survival following curative gastrectomy for gastric carcinoma. Arch Surg 1991;26:359–64.

    Google Scholar 

  33. Adachi Y, Kamakura T, Mori M, Maechara Y, Sugimachi K. Role of lymph node dissection and splenectomy in node positive gastric carcinoma. Surgery 1994;116:837–41.

    PubMed  CAS  Google Scholar 

  34. Griffith JP, Sue-Ling HM, Dixon MF, McMahon MJ, Axon ATR, Johnston D. Preservation of spleen improves survival after radical surgery for gastric cancer. Gut 1995;36:684–90.

    PubMed  CAS  Google Scholar 

  35. Otsuji E, Yamaguchi T, Sawai K, Ohara M, Takahashi T. End results of simultaneous splenectomy in patients undergoing total gastrectomy for gastric carcinoma. Surgery 1996;120:40–4.

    PubMed  CAS  Google Scholar 

  36. Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745–8.

    Article  CAS  PubMed  Google Scholar 

  37. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. Lancet 1996;347:995–9.

    Article  PubMed  CAS  Google Scholar 

  38. Wanebo HJ, Kennedy BJ, Winchester DP, Stewart A, Fremgen M. Role of splenectomy in gastric cancer surgery: adverse effect of elective splenectomy on longterm survival. J Am Coll Surg 1997;185:177–84.

    PubMed  CAS  Google Scholar 

  39. Stipa S, DiGiorgio A, Ferri M, Botti C. Results of curative gastrectomy for carcinoma. J Am Coll Surg 1994;17:567–72.

    Google Scholar 

  40. Kwon SJ. Prognostic impact of splenectomy on gastric cancer: results of the Korean gastric cancer study group. World J Surg 1997;21:837–44.

    PubMed  CAS  Google Scholar 

  41. Marujama K, Sasako M, Kinoshita T, Sano T, Katai H, Okajima K. Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 1995;19:532–6.

    Google Scholar 

  42. Hermanek P, Sobin LH, eds. UICC. TNM classification of malignant tumours, 4th ed. Berlin: Springer-Verlag, 1987.

    Google Scholar 

  43. Okusa T, Nakane Y, Boku T, et al. Quantitative analysis of nodal involvement with respect to survival rate after curative gastrectomy for carcinoma. Surg Gynecol Obstet 1990;170:488–94.

    PubMed  CAS  Google Scholar 

  44. Isozaki H, Okajima K, Kawashima Y, et al. Prognostic value of the number of metastatic lymph nodes in gastric cancer with radical surgery. J Surg Oncol 1993;53:247–51.

    PubMed  CAS  Google Scholar 

  45. Makino M, Moriwaki S, Yonekawa M, Oota M, Kaibara N. Prognostic significance of the number of metastatic lymph nodes in patients with gastric cancer. J Surg Oncol 1991;47:12–16.

    PubMed  CAS  Google Scholar 

  46. Ichikura T, Tomimatsu S, Uefuji K, et al. Composition of the prognostic significance between nodal stage according to general rules for gastric cancer [in Japanese]. Japanese Journal of Gastroenterological Surgery 1993;26:1963–8.

    Google Scholar 

  47. Shiu MH, Moore E, Sanders M, Huvos A, Freedman B, Goodbold J. Influence of the extent of resection on survival after curative treatment of gastric carcinoma. Arch Surg 1987;122:1347–51.

    PubMed  CAS  Google Scholar 

  48. Jaehne J, Meyer HJ, Maschek H, Geerlings H, Bruns E, Pichlmayr R. Lymphadenectomy in gastric carcinoma. Arch Surg 1992;127:290–4.

    PubMed  CAS  Google Scholar 

  49. Boettcher K, Becker K, Busch R, Roder JD, Siewert JR. Prognosefaktoren beim Magen-karzinom: Ergebnisse einer uni- und multivariaten Analyse. Chirurg 1992;63:656–61.

    Google Scholar 

  50. Roder JD, Boettcher K, Siewert JR, Busch R, Hermanek P, Meyer HJ, and the German Gastric Carcinoma Study Group. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer 1993;72:2089–97.

    CAS  PubMed  Google Scholar 

  51. Sbin LH, Wittekind CH, eds. TNM classification of malignant tumours. International Union Against Cancer. 5th ed. New York: John Wiley & Sons, 1997.

    Google Scholar 

  52. Kodama Y, Sugimachi K, Soejima K, Matusaka T, Inokuchi K. Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg 1981;5:241–8.

    CAS  PubMed  Google Scholar 

  53. Pacelli F, Doglieto GB, Bellantone R, Alfieri S, Sgadari A, Crucitti F. Extensive versus limited lymph node dissection for gastric cancer: a comparative study of 320 patients. Br J Surg 1993;80:1153–6.

    PubMed  CAS  Google Scholar 

  54. Roukos D, Hottenrott C, Lorenz M, Koutsogiorgas-Couchell S. A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach. J Cancer Res Clin Oncol 1990;116:307–13.

    PubMed  CAS  Google Scholar 

  55. Soreide JA, van-Heerden JA, Burger LJ, Donohue JH, Sarr MG, Ilstrup DM. Surgical aspects of patients with adenocarcinoma operated on for cure. Arch Surg 1996;131:481–6.

    PubMed  CAS  Google Scholar 

  56. Wanebo HJ, Kennedy BJ, Winchester DP, Fremgen A, Stewart AK. Gastric carcinoma. Does lymph node dissection alter survival? J Am Coll Surg 1996;183:616–24.

    PubMed  CAS  Google Scholar 

  57. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604–8.

    Article  PubMed  CAS  Google Scholar 

  58. Roukos DH, Kappas AM, Encke A. Extensive lymph node dissection in gastric cancer: is it of therapeutic value? Editorial. Cancer Treat Rev 1996;22:247–52.

    PubMed  CAS  Google Scholar 

  59. Bunt AMG, Hermans J, Smit VTHBM, van de Velde CJH, Fleuren GJ, Bruijn JA. Surgical/pathologic-stage migration confounds comparison of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 1995;13:19–25.

    CAS  PubMed  Google Scholar 

  60. Fass J, Hungs M, Reineke TH, Schumpelic V. The impact of D2-lymphadenectomy on staging and prognosis of gastric carcinoma. In: Siewert JR, Roder JD, eds. Proceedings of the 2nd International Gastric Cancer Congress, Munich, 1997; 2:1141–46.

  61. Harrison LE, Karpeh MS, Brennan MF. Extended lymphadenectomy is associated with a survival benefit for node-negative gastric cancer. In: Siewert JR, Roder JD, eds. Proceedings of the 2nd International Gastric Cancer Congress, Munich, 1997;2:1151–4.

  62. Kaibara N, Sumi K, Yonekawa M, et al. Does extensive dissection of lymph nodes improve the results of surgical treatment of gastric cancer? Am J Surg 1990;159:218–21.

    PubMed  CAS  Google Scholar 

  63. Korenaga D, Moriguchi S, Orita H, et al. Trends in survival rates in Japanese patients with advanced carcinoma of the stomach. Surg Gynecol Obstet 1992;174:387–93.

    PubMed  CAS  Google Scholar 

  64. Averbach AM, Jacquet P. Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Br J Surg 1996;83:726–33.

    PubMed  CAS  Google Scholar 

  65. McCulloch PG, Ochiai A, O’Dowd GM, Nashi JRG, Sasako M, Hirohashi S. Comparison of the molecular genetics of c-erb-B2 and p53 expression in stomach cancer in Britain and Japan. Cancer 1995;75:920–5.

    PubMed  CAS  Google Scholar 

  66. Dent DM, Madden MV, Price SK. Randomised comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988;75:110–12.

    PubMed  CAS  Google Scholar 

  67. Smith JW, Shiu MH, Kelsey L, Brennan MF. Morbidity of radical lymphadenectomy in the curative resection of gastric carcinoma. Arch Surg 1991;126:1469–73.

    PubMed  CAS  Google Scholar 

  68. Sue-Ling HM, Johnston D, Martin IG, et al. Gastric cancer: a curable disease in Britain. Br Med J 1993;307:591–6.

    Article  CAS  Google Scholar 

  69. Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended lymphadenectomy in Western gastric cancer patients based on a new concept. A prospective long-term follow-up study. Surgery 1998;123:573–8.

    CAS  Google Scholar 

  70. Sano T, Martin IG. Lymphadenectomy and pancreaticosplenectomy in gastric cancer surgery. Letter. Lancet 1996;348:195–6.

    CAS  Google Scholar 

  71. Bonenkamp JJ, van de Velde CJH, Hermans J. Randomised trial of extended lymph node dissection for gastric cancer. In: Siewert JR, Roder JD, eds. Proceedings of the 2nd International Gastric Cancer Congress, Munich, 1997;2:1111–6.

  72. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: metaanalysis of randomized trials. J Clin Oncol 1993;11:1441–7.

    CAS  PubMed  Google Scholar 

  73. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979;39:3861–5.

    PubMed  CAS  Google Scholar 

  74. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy in kinetics and growth of metastases. Cancer Res 1983;43:1488–92.

    PubMed  CAS  Google Scholar 

  75. Fink U, Schumacher C, Stein HJ, et al. Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg 1995;82:1248–52.

    PubMed  CAS  Google Scholar 

  76. Grundei T, Fink U, Matzen K, et al. Neoadjuvant chemotherapy with cisplatin, leucovorin and 5 fluorouracil (PLF) for locally advanced gastric cancer. In: Siewert JR, Roder JD, eds. Proceedings of the 2nd International Gastric Cancer Congress, Munich, 1997;2:1323–6.

  77. Kang YK, Choi DW, Im YH, et al. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery for locally advanced stomach cancer. Abstract. Proc Am Soc Clin Oncol 1996;15:215.

    Google Scholar 

  78. Yonemura Y, Sawa T, Kinoshita K, et al. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993;17:256–62.

    PubMed  CAS  Google Scholar 

  79. Iitsuka Y, Kaneshima S, Taneda O, Takeuchi T, Koga S. Intraperitoneal free cancer cells and their viability in gastric cancer. Cancer 1979;44:1476–80.

    PubMed  CAS  Google Scholar 

  80. Hansen E, Wolff N, Kneuchel R, Ruschoff J, Hofstaedter F, Taeger K. Tumour cells in blood shed from the surgical field. Arch Surg 1995;130:387–93.

    PubMed  CAS  Google Scholar 

  81. Koga S, Kaibara N, Iitsuka Y, Kudo H, Kimura A, Horaoka H. Prognostic significance of intraperitoneal free cancer cells in gastric cancer patients. J Cancer Res Clin Oncol 1984;110:236–38.

    Google Scholar 

  82. Baba H, Korenaga D, Haraguchi M, et al. Width of serosal invasion and prognosis in advanced human gastric cancer with special reference to the mode of tumor invasion. Cancer 1989;64:2482–6.

    PubMed  CAS  Google Scholar 

  83. Haraguchi M, Watanabe A, Kakeji Y, et al. Prognostic significance of serosal invasion in carcinoma of the stomach. Surg Gynecol Obstet 1991;172:29–32.

    PubMed  CAS  Google Scholar 

  84. Takahashi T, Hagiwara A, Shimotsuma M, Sawai K, Yamaguchi T. Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. World J Surg 1995;19:565–69.

    PubMed  CAS  Google Scholar 

  85. Fass J, Asshoff G, Zengel K, Reinicke T, Schumpelicj V. Prophylactic intraperitoneal therapy with carbon-absorbed mitomycin in gastric cancer with serosal invasion. Preliminary results of a prospective randomized trial. In: Siewert JR, Roder JD, eds. Proceedings of the 2nd International Gastric Cancer Congress, Munich, 1997;2:1359–64.

  86. Kelsen DP. Phase III study of neoadjuvant FAMTX with postoperative randomization to intraperitoneal FUDR/CF versus observation for patients with high-risk gastric cancer. In: National Cancer Institute. Current Clinical Trials: Oncology. Green Brook, NJ: Pyros Educational Group, 1995:560.

Download references

Author information

Authors and Affiliations

  1. Academic Department of Surgery, Medical School, University of Ioannina, GR-451 10, Ioannina, Greece

    Dimitrios H. Roukos MD

Authors
  1. Dimitrios H. Roukos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roukos, D.H. Current Advances and Changes in Treatment Strategy May Improve Survival and Quality of Life in Patients With Potentially Curable Gastric Cancer. Ann Surg Oncol 6, 46–56 (1999). https://doi.org/10.1007/s10434-999-0046-z

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10434-999-0046-z

Key Words

Search

Navigation